Brief: Poxel To Present Imeglimin Phase 3 Results For TIMES 2 and TIMES 3 And New Results For PXL770 At 56th EASD Annual Meeting

Poxel SA

24/09/2020 07:08

Sept 24 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL PRESENTS IMEGLIMIN PHASE 3 TIMES RESULTS AND PXL770
PRECLINICAL CARDIO-RENAL RESULTS AT THE 56TH EUROPEAN
ASSOCIATION FOR THE STUDY OF DIABETES ANNUAL MEETING
    * PHASE 3 TIMES 2 AND TIMES 3 TRIAL RESULTS DEMONSTRATE THAT
IMEGLIMIN MET ITS PRIMARY ENDPOINTS AND OBJECTIVES AND WAS
OBSERVED TO EXHIBIT A FAVORABLE SAFETY AND TOLERABILITY PROFILE
    * PXL770, A DIRECT AMPK ACTIVATOR, WAS OBSERVED TO IMPROVE
RENAL
AND CARDIAC DISEASE IN A PRECLINICAL MODEL DEMONSTRATING UTILITY
FOR NASH CO-MORBIDITIES AND ADDITIONAL INDICATIONS DRIVEN BY
METABOLIC DYSFUNCTION

Source text for Eikon:  ID:nBw8f5VJ0a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))